GlassScriptPhysician profile
Sufyan Ahmad
NPI 1326779349
$743.41
in general payments reported to CMS, 2019-2025
10 companies · $708 in 2025
The $708 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $35.37 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $743.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $179.59 | 2025 | Ozempic, Wegovy |
| Amgen INC. | $171.68 | 2025 | Repatha, Otezla |
| Lilly USA, LLC | $160.50 | 2025 | Zepbound, Mounjaro |
| Kowa Pharmaceuticals America, INC. | $64.47 | 2025 | Zoryve |
| Astrazeneca Pharmaceuticals LP | $43.19 | 2025 | Airsupra |
| Si-Bone, INC. | $35.37 | 2024 | |
| Corcept Therapeutics | $28.29 | 2025 | Korlym |
| Pfizer INC. | $25.17 | 2025 | |
| Hologic Sales and Service, LLC | $19.72 | 2025 | Aptima, Thinprep 2000 Processor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.43 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sufyan Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.